Literature DB >> 31421441

Rapid and automated production of [68Ga]gallium chloride and [68Ga]Ga-DOTA-TATE on a medical cyclotron.

William Tieu1, Courtney A Hollis2, Kevin K W Kuan2, Prab Takhar2, Mick Stuckings3, Nigel Spooner4, Mario Malinconico5.   

Abstract

INTRODUCTION: The demand for Gallium-68 (68Ga) for labelling PET radiopharmaceuticals has increased over the past few years. 68Ga is obtained through the decayed parent radionuclide 68Ge using commercial 68Ge/68Ga generators. The principal limitation of commercial 68Ge/68Ga generators is that only a limited and finite quantity of 68Ga (<1.85 GBq at start of synthesis) may be accessed. The focus of this study was to investigate the use of a low energy medical cyclotron for the production of greater quantities of 68Ga and to develop an automated and rapid procedure for processing the product.
METHODS: Enriched ZnCl2 was electrodeposited on a platinum backing using a NH4Cl (pH 2-4) buffer. The Zn target was irradiated with GE PETtrace 880 at 35 μA and 14.5 and 12.0 MeV beam energy. The irradiated Zn target was purified using octanol resin on an automated system.
RESULTS: Following the described procedure, 68Ga was obtained in 6.30 ± 0.42 GBq after 8.5 min bombardment and with low radionuclidic impurities (66Ga (<0.005%) and 67Ga (<0.09%)). Purification on a single octanol resin gave 82% recovery with resulting [68Ga]GaCl3 obtained in 3.5 mL of 0.2 M HCl. [68Ga]GaCl3 production from irradiation to final product was <45 min. To highlight the utility of the automated procedure, [68Ga]Ga-DOTA-TATE labelling was incorporated to give 1.56 GBq at EOS of the labelled peptide with RCY of >70%.
CONCLUSIONS: A straightforward procedure for producing 68Ga on a low energy medical cyclotron was described. Current efforts are focus on high activity production and radiolabelling using solid target produced 68Ga. Crown
Copyright © 2019. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cyclotron; DOTA-TATE; Ga-68; PET; Solid targetry

Mesh:

Substances:

Year:  2019        PMID: 31421441     DOI: 10.1016/j.nucmedbio.2019.07.005

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  4 in total

1.  Total Body PET: Why, How, What for?

Authors:  Suleman Surti; Austin R Pantel; Joel S Karp
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2020-04-03

2.  Analysis of Pros and Cons in Using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer.

Authors:  Costantina Maisto; Michela Aurilio; Anna Morisco; Roberta de Marino; Monica Josefa Buonanno Recchimuzzo; Luciano Carideo; Laura D'Ambrosio; Francesca Di Gennaro; Aureliana Esposito; Paolo Gaballo; Valentina Pirozzi Palmese; Valentina Porfidia; Marco Raddi; Alfredo Rossi; Elisabetta Squame; Secondo Lastoria
Journal:  Molecules       Date:  2022-06-16       Impact factor: 4.927

Review 3.  Good practices for 68Ga radiopharmaceutical production.

Authors:  Bryce J B Nelson; Jan D Andersson; Frank Wuest; Sarah Spreckelmeyer
Journal:  EJNMMI Radiopharm Chem       Date:  2022-10-22

4.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.